新里程：公司后续将通过降低销售费率等，持续加强销售能力建设

Core Viewpoint - The company reported a loss in the first three quarters due to changes in centralized procurement prices and transitional market acceptance issues, but there are signs of recovery in sales since September [1] Group 1: Financial Performance - The company experienced a loss in the first three quarters of the year due to reduced profit margins from centralized procurement price changes and market acceptance during the transition period [1] - Sales strategies have been adjusted to improve performance, focusing on refined management of the agent market and increasing coverage of grassroots medical institutions [1] Group 2: Sales and Marketing Strategies - The company is guiding agents to switch to larger specification products and providing greater profit margins to enhance sales [1] - Future plans include lowering sales commission rates, expanding into the retail market, and strengthening e-commerce channel development to boost sales capabilities [1] Group 3: Operational Improvements - The company aims to inject new product resources into its pharmaceutical segment through self-research, external product business development, and pharmaceutical acquisitions [1] - Efforts will be made to optimize organizational structure, reduce labor costs, control expenses based on budgets, and centralize production to save costs and improve performance in the pharmaceutical sector [1]